{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T03:12:25Z","timestamp":1722913945766},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.diagmicrobio.2016.12.009","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T06:02:41Z","timestamp":1481695361000},"page":"268-271","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates"],"prefix":"10.1016","volume":"87","author":[{"given":"Jennifer I.","family":"Smart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Ralph","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Stryjewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whedy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Barriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0010","series-title":"Twenty-fourth informational supplement (M100-S24)","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0015","series-title":"Twenty-sixth international Suppplement (M100-S26)","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0020","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1128\/JCM.00640-06","article-title":"Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using Gram-positive organisms","volume":"44","author":"Fritsche","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","article-title":"Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations","volume":"204","author":"Holmes","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0030","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.ijid.2012.08.005","article-title":"High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis","volume":"17","author":"Jacob","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkh156","article-title":"Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria","volume":"53","author":"King","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0045","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","article-title":"Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method","volume":"81","author":"Mendes","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0055","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1128\/AAC.00011-12","article-title":"Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0060","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1128\/AAC.47.11.3602-3604.2003","article-title":"In vitro activity of TD-6424 against Staphylococcus aureus","volume":"47","author":"Pace","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0065","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/jac\/dkq335","article-title":"Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia","volume":"65","author":"Pfaller","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0070","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/JCM.01210-14","article-title":"Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method","volume":"52","author":"Ross","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jac\/dkm211","article-title":"Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus","volume":"60","author":"Saravolatz","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0080","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1128\/AAC.00773-15","article-title":"Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic\/pharmacodynamic models","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0090","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0095","series-title":"VIBATIV\u00ae (telavancin), USP [package insert]","author":"VIBATIV\u00ae [package insert]","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2016.12.009_bb0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijantimicag.2013.07.010","article-title":"High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate S. aureus in meticillin-resistant S. aureus bacteraemia patients","volume":"42","author":"Wang","year":"2013","journal-title":"Int J Antimicrob Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316304278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316304278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T01:28:19Z","timestamp":1536197299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316304278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0732889316304278"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.12.009","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}